How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/prophylaxis-of-stage-tag1-papillary-tumors-at-high-risk-of-tumor-recurrence.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Prophylaxis of stage TaG1 papillary tumors at high risk of tumor recurrence — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prophylaxis of stage TaG1 papillary tumors at high risk of tumor recurrence (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Prophylaxis of stage TaG1 papillary tumors at high risk of tumor recurrence, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Tice Bcg	bacillus-calmette-guerin	Pfizer	Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]	Mycobacterium tuberculosis

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 1 drug in Prophylaxis of stage TaG1 papillary tumors at high risk of tumor recurrence

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Prophylaxis of stage TaG1 papillary tumors at high risk of tumor recurrence:

Cite this brief

Drug Landscape (2026). Prophylaxis of stage TaG1 papillary tumors at high risk of tumor recurrence — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/prophylaxis-of-stage-tag1-papillary-tumors-at-high-risk-of-tumor-recurrence. Accessed 2026-06-10.

Prophylaxis of stage TaG1 papillary tumors at high risk of tumor recurrence full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing